Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 101,264 |
|
|||||
| News | - | ||||||
| Day High | 1.75 | Low High |
|||||
| Day Low | 1.71 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ikena Oncology Inc | IKNA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.035 | -1.99% | 1.725 | 15:40:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.73 | 1.71 | 1.75 | 1.76 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 956 | 101,264 | $ 1.73 | $ 174,825 | - | 1.02 - 7.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:42:12 | 29 | $ 1.73 | USD |
Ikena Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 83M | 48.26M | - | 9.16M | -68.17M | -1.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ikena Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IKNA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.72 | 1.88 | 1.65 | 1.78 | 338,359 | 0.005 | 0.29% |
| 1 Month | 1.34 | 1.88 | 1.28 | 1.59 | 480,299 | 0.385 | 28.73% |
| 3 Months | 1.45 | 1.88 | 1.22 | 1.48 | 337,478 | 0.275 | 18.97% |
| 6 Months | 1.70 | 2.32 | 1.22 | 1.50 | 345,046 | 0.025 | 1.47% |
| 1 Year | 6.99 | 7.38 | 1.02 | 2.21 | 249,553 | -5.27 | -75.32% |
| 3 Years | 15.71 | 17.60 | 1.02 | 4.98 | 170,097 | -13.99 | -89.02% |
| 5 Years | 22.40 | 37.61 | 1.02 | 6.34 | 174,002 | -20.68 | -92.30% |
Ikena Oncology Description
| Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. |
